Cangrelor bulk supplier for pharma manufacturers

Cangrelor 50 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 50 mg

Reference Brands: Kengreal (USA/EU)

Cangrelor is a Heart Disorder product available as Injection in strengths 50 mg. It corresponds to the reference brand Kengreal (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Cangrelor? List it or send an offer →

Product Description:

Cangrelor is a potent, fast-acting intravenous antiplatelet agent approved for use in patients undergoing percutaneous coronary intervention (PCI). It is indicated to reduce the risk of thrombotic cardiovascular events in patients who have not been treated with oral P2Y12 inhibitors or who are unable to receive oral antiplatelet therapy. The clinical efficacy of cangrelor is attributed to its direct, reversible inhibition of the P2Y12 platelet receptor, resulting in rapid and consistent platelet inhibition.

Cangrelor is characterized by an immediate onset of action and a very short half-life, allowing for precise control of antiplatelet effects during and immediately after PCI. Its pharmacokinetic and pharmacodynamic profile enables quick recovery of platelet function once the infusion is discontinued, making it suitable for use in acute and procedural settings.

The drug is generally well tolerated, though healthcare professionals should remain aware of potential adverse drug reactions, contraindications, and drug interactions associated with antiplatelet therapy. Proper patient selection, dosing, and monitoring are essential to optimize clinical outcomes. Effective interprofessional collaboration among cardiologists, pharmacists, and nursing staff plays a critical role in ensuring the safe and effective use of cangrelor in cardiovascular care.

Cangrelor — third party manufacturing & bulk supply

Cangrelor 50 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Cangrelor is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Cangrelor listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Cangrelor →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Cangrelor is used as an intravenous antiplatelet agent to reduce the risk of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). It is especially useful in patients who have not been pretreated with oral P2Y12 inhibitors or who are unable to take oral antiplatelet therapy.

Cangrelor is a synthetic adenosine triphosphate analog. It is chemically designed to reversibly inhibit platelet activation by targeting the P2Y12 receptor.

Cangrelor is marketed under the trade names Kengreal in the United States and Kengrexal in the European Union and the United Kingdom.

Cangrelor was developed by The Medicines Company. It is currently marketed by Chiesi Farmaceutici in the EU and UK, and by Chiesi USA for the US market.

The generic name is cangrelor.

The brand names are Kengreal and Kengrexal.

Cangrelor is manufactured in GMP-approved pharmaceutical facilities, with production and supply distributed across the USA and Europe according to regional regulatory approvals.